These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 7617182

  • 1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1995 Jul; 45(7):1277-85. PubMed ID: 7617182
    [Abstract] [Full Text] [Related]

  • 2. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 3. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A.
    Mult Scler; 2009 Oct 22; 15(10):1195-205. PubMed ID: 19797261
    [Abstract] [Full Text] [Related]

  • 4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 22; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr 22; 43(4):655-61. PubMed ID: 8469318
    [Abstract] [Full Text] [Related]

  • 6. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 22; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 22; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 8. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O, Antigüedad A, Arbizu T, Burgués S, Capdevila A, de Castro P, Correa de Sá JC, García-Merino JA, Izquierdo G, Magalhaes A, Montalbán X, Zarranz JJ.
    Rev Neurol; 2008 Jun 22; 29(12):1093-9. PubMed ID: 10652728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E.
    Ann Neurol; 2004 Oct 22; 56(4):548-55. PubMed ID: 15389896
    [Abstract] [Full Text] [Related]

  • 11. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 22; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J, Francis G, Chang P, PRISMS Study Group.
    J Neurol Sci; 2005 Oct 15; 237(1-2):45-52. PubMed ID: 16026803
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH.
    Ann Neurol; 1998 Jan 15; 43(1):79-87. PubMed ID: 9450771
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.